Medlab Clinical (ASX:MDC) - CEO, Dr Sean Hall
CEO, Dr Sean Hall
Sourced: Medlab
Market Herald logo


Be the first with the news that moves the market
  • Medlab Clinical (MDC) has completed the intervention stage of its depression trial using its patented NRGBiotic product
  • The study has been conducted by the Queensland University of Technology
  • NRGBiotic is a multi-patented probiotic available throughout Australian pharmacies
  • The formula supports cellular energy production as well as a healthy gut and immune system
  • For the next three months, Medlab will conduct a pathology and independent review of the results
  • Medlab is up 15.8 per cent and shares are trading for 22 cents each

Medlab Clinical (MDC) has completed the intervention stage of the Queensland University of Technology (QUT) depression trial using the NRGBiotic product.

NRGBiotic is a multi-patented probiotic available throughout Australian pharmacies.

The probiotic formula is combined with Coenzyme Q10 and Magnesium Orotate. Its purpose is to support healthy cellular energy production, with magnesium and Coenzyme Q10 required to create energy in the cell. The probiotic may also help support a healthy gut and a healthy immune system.

The trial followed on from previous trials investigating the use of NRGBiotic versus placebo used with common antidepressant medications for people diagnosed with depression that were getting little or no relief from standard medical treatment.

Since it began, this trial has received Government grants of $75,000 which validates the need for a wider range of medications.

“The completion of a randomised placebo-controlled study with patients diagnosed with major depression unresponsive to standard pharmaceutical medications is a significant milestone achievement for Medlab’s research group,” Medlab Director of Medical Research Professor Luis Vitetta said.

“I am very pleased we have been able to fulfil our research duties with minimal interference to participants, and whilst the intervention stage is completed, the trial cohort will for the next 3 months focus on testing outcomes and independent analysis of those results,” CEO Dr Sean Hall said.

The company will now wait for the data that will provide links between the gut bacteria cohort, blood metabolites and mood; and the level of treatment efficacy achieved for depression.

Medlab is up 15.8 per cent and shares are trading for 22 cents each at 3:57 pm AEDT.

MDC by the numbers
More From The Market Herald
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp (ASX:RAP) completes recruitment for Indian COVID-19 study

ResApp Health (RAP) has completed the recruitment ahead of schedule for its Indian COVID-19 clinical study.